Skip to content

Application of remidazolam combined with sufentanil in endoscopic ultrasonography guided transbronchial examination and treatment

Application of remidazolam combined with sufentanil in endoscopic ultrasonography guided transbronchial examination and treatment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063627
Enrollment
Unknown
Registered
2022-09-13
Start date
2022-09-13
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia of patients undergoing bronchial needle aspiration biopsy

Interventions

Remazolam group:Sedation and anesthesia with remazolam
Propofol group:Propofol sedation anesthesia

Sponsors

The Second Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients requiring EBUS-TBNA (2) The patient was informed and voluntarily participated in the study, and signed the informed consent (3) Aged between 18 and 65 (4) ASA classification II - III (5)18.5 kg / m2 90%

Exclusion criteria

Exclusion criteria: (1) Severe arrhythmia was found (2) Pregnant woman (3) Have a history of sedative and analgesic drug dependence (4) Allergic reaction to the drugs used in this study (5) Those who have contraindications to the drugs used in this study (6) Severe pulmonary insufficiency (7) Patients with severe chronic heart failure (8) Patients with hepatic and renal insufficiency (9) Patients with severe chronic pain (10) Patients with severe mental and neurological diseases

Design outcomes

Primary

MeasureTime frame
Times of respiratory depression;

Secondary

MeasureTime frame
Qor-40 scale score;Recovery time of patients;VAS pain score;Patient's intraoperative vital signs;

Countries

China

Contacts

Public ContactMingjian Kong
mjkong@126.com17751991669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026